Celanese Corporation
CE
$47.52
-0.75%
Celanese Corporation is one of the world's largest producers of acetic acid and its downstream derivative chemicals, serving end markets including coatings, adhesives, automotive, electronics, medical, building, and consumer applications, alongside a leading specialty polymers franchise and cellulose derivatives used in cigarette filters. The company operates as a scaled, integrated chemical manufacturer with two core reporting segments — Engineered Materials (the larger at roughly $1.33 billion in quarterly revenue) and the Acetyl Chain (roughly $1.04 billion) — giving it a distinct position as both a commodity-linked acetyl producer and a higher-value specialty materials supplier. The current investor narrative is dominated by a deeply challenged earnings picture: a massive Q3 2025 impairment-driven loss of $1.36 billion, a Q4 2024 loss of $1.91 billion, negative trailing net margin of roughly -12%, and a debt-heavy balance sheet with debt-to-equity above 3.1x, all of which have pushed the stock down sharply over the past six months. Debate now centers on whether the company's cost actions, portfolio moves (including asset sale proceeds visible in Q1 2026 investing cash flow), and forward EPS recovery toward roughly $12 can stabilize the story, or whether weak acetyl chain pricing and elevated leverage will keep the equity under pressure.…
CE
Celanese Corporation
$47.52
Investment Opinion: Should I buy CE Today?
We assign a Hold rating on Celanese. The core thesis is that the stock is deeply discounted on forward earnings (7.19x forward PE) and offers 42.8% upside to the average analyst target of $63.12, but these positives are offset by extreme leverage (debt-to-equity of 3.19x), negative trailing profitability (net margin -12.21%), and revenue stagnation. The consensus recommendation is 'buy' with a mean of 1.82, but the wide target range ($45-$86) and recent underperformance suggest caution. The risk/reward is balanced but skewed toward high risk until there is clearer evidence of sustainable earnings recovery and deleveraging.
Supporting evidence for the Hold includes: 1) Forward PE of 7.19x is well below the broader market and specialty chemical peers, implying significant undervaluation if EPS recovers to $11.95; 2) TTM free cash flow of $878 million provides some financial flexibility, though Q1 2026 FCF was only $10 million; 3) Revenue has been stable around $2.3 billion but is not growing, with Q1 2026 down 2.18% YoY; 4) Gross margin has compressed to 18.96% from over 21% in mid-2025, indicating pricing pressure; 5) The implied upside to the average analyst target is 42.8%, but the low target of $45 is only 1.8% above the current price, highlighting downside risk. The PS ratio of 0.485x is near historic lows, but this reflects the market's concern about leverage and earnings quality.
The biggest risks that could invalidate the thesis are: 1) A failure to deleverage, with interest coverage at 1.03x leaving no room for earnings declines; 2) A continued decline in acetyl chain pricing or volumes, which would pressure margins further; 3) A broader economic slowdown that reduces demand for specialty materials. The rating would upgrade to Buy if the company demonstrates two consecutive quarters of positive net income and reduces debt-to-equity below 2.5x, or if forward EPS estimates are revised upward. It would downgrade to Sell if interest coverage falls below 1.0x, free cash flow turns negative, or revenue declines accelerate. Relative to its history, the stock is undervalued on P/B (1.14x vs. historical 2-4x) and PS (0.485x vs. 5.61x in Q3 2024), but the discount is warranted by fundamental deterioration. We view the stock as fairly valued at current levels, with a bias toward undervaluation only if the recovery materializes.
Sign up to view all
CE 12-Month Price Forecast
We maintain a neutral stance on Celanese with medium confidence. The stock is deeply undervalued on forward earnings, but the recovery is highly uncertain given the company's leveraged balance sheet and cyclical end markets. The bull case hinges on successful deleveraging and margin normalization, while the bear case fears a liquidity crunch if earnings disappoint. The wide analyst target range ($45-$86) reflects this uncertainty. We would upgrade to bullish if the company reports two consecutive quarters of positive net income and reduces debt-to-equity below 2.5x. We would downgrade to bearish if interest coverage falls below 1.0x or free cash flow turns negative. The risk/reward is balanced, but the high leverage makes this a speculative investment at current levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Celanese Corporation's 12-month outlook, with a consensus price target around $61.17 and implied upside of +28.7% versus the current price.
Average Target
$61.17
0 analysts
Implied Upside
+28.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$46 - $86
Analyst target range
Coverage is solid, with 17 analysts covering Celanese. The consensus recommendation is "buy" with a recommendation mean of 1.82 (where 1.0 is a strong buy and 5.0 is a sell), indicating a moderately bullish tilt. The average price target is $63.12, which implies roughly +42.8% upside from the current price of $44.19 — a substantial gap that suggests analysts see significant recovery potential. However, the consensus is not uniformly bullish: recent institutional ratings show a mix of Buy/Overweight calls (B of A, Citigroup, Wells Fargo, JP Morgan's May upgrade to Overweight) alongside Neutral/Market Perform/Sector Perform ratings from Mizuho, BMO Capital, and RBC Capital, indicating meaningful disagreement about the pace of recovery.
The target range is exceptionally wide, spanning from a low of $45.00 to a high of $86.00 — a spread of $41, or roughly 91% of the low target — which signals very high uncertainty about the company's trajectory. The high target of $86 implies a full earnings normalization, successful deleveraging, and multiple expansion back toward historical norms, while the low target of $45 (just 1.8% above the current price) prices in continued margin compression, weak acetyl chain pricing, and the risk that leverage constrains strategic flexibility. Notably, the low target is essentially at the current price, meaning the most bearish analyst sees no upside at all. The wide dispersion, combined with the recent JP Morgan upgrade to Overweight in May 2026 and the cluster of Neutral ratings, suggests analysts are divided between a deep-value recovery thesis and a structurally challenged, over-levered cyclical — investors should treat the consensus target with caution given the 91% spread and the fact that the stock has consistently underperformed even the low end of the range over the past six months.
Drowning in data?
Find the real signal!
Bulls vs Bears: CE Investment Factors
The bear case currently has stronger evidence due to the company's extreme leverage, negative trailing profitability, and revenue stagnation. The bull case rests on a dramatic forward EPS recovery to $11.95 and deep value multiples, but this requires successful deleveraging and margin normalization that have yet to materialize. The most critical tension is whether the Q1 2026 return to positive net income ($44 million) marks a sustainable inflection or merely a temporary reprieve before another downturn. If forward estimates prove overly optimistic, the stock could retest its 52-week low of $35.13, representing 20% downside; conversely, if earnings normalize, the 43% upside to analyst targets is compelling.
Bullish
- Deep value on forward earnings: Forward PE of 7.19x is extremely low, implying the market expects EPS to recover to $11.95 from trailing -$0.25. If the company hits even the low end of analyst estimates ($11.05), the stock would still trade at just 4x forward earnings, suggesting significant undervaluation.
- Analyst consensus sees 43% upside: The average analyst target price is $63.12, representing 42.8% upside from the current $44.19. With 17 analysts covering and a consensus recommendation of 'buy' (mean 1.82), the sell-side is overwhelmingly positive despite recent losses.
- Strong free cash flow generation: TTM free cash flow is $878 million, and Q1 2026 FCF was positive at $10 million after $66 million of capex. This cash generation supports deleveraging and provides a cushion against cyclical downturns.
- Asset sales bolster liquidity: Cash increased to $1.758 billion at Q1 2026 from $1.263 billion at year-end 2025, thanks to $493 million in asset-sale proceeds. This improves financial flexibility and reduces near-term solvency risk.
Bearish
- Extreme leverage threatens solvency: Debt-to-equity is 3.19x and total debt-to-capitalization is 75.5%, with interest coverage of just 1.03x. Q1 2026 interest expense of $183 million nearly consumed all operating income of $189 million, leaving almost no margin for error.
- Negative trailing profitability: Trailing net margin is -12.21% and trailing EPS is -$0.25, reflecting massive impairment charges: Q3 2025 loss of $1.36 billion and Q4 2024 loss of $1.91 billion. ROE is -28.77%, indicating severe capital destruction.
- Revenue stagnation and margin compression: Q1 2026 revenue declined 2.18% year-over-year to $2.337 billion, and gross margin has fallen from 21.54% in Q3 2025 to 18.96% in Q1 2026. The top line has been range-bound between $2.2B and $2.5B for several quarters with no growth catalyst.
- Severe relative underperformance: The stock has underperformed SPY by 48.37 percentage points over six months and 10.66 points over three months. This persistent weakness suggests deep-seated fundamental issues rather than temporary market disfavor.
CE Technical Analysis
Celanese is in a clear, sustained downtrend that has only recently begun to flatten. The stock is down 2.47% over the past year and a punishing 31.02% over six months, with the current price of $44.19 sitting at just 26.9% of its 52-week range (52-week low of $35.13, high of $70.70). That positioning near the bottom of the annual range signals persistent distribution and a market that has largely priced in deteriorating fundamentals rather than a momentum-driven overextension — though it also means the stock is a falling-knife candidate until a base forms. Notably, the year-to-date change is actually positive at +4.82%, implying the worst of the decline occurred in the back half of 2025 and the stock has been attempting to stabilize in 2026.
Short-term momentum remains weak and is diverging negatively from the already-soft longer-term trend. The 1-month change is -5.29% and the 3-month change is -7.32%, both worse than the -2.47% 1-year figure, indicating the decline has re-accelerated recently rather than decelerating. Relative strength confirms the underperformance: CE trails SPY by 5.88 percentage points over 1 month, 10.66 points over 3 months, and a staggering 48.37 points over 6 months, while SPY itself gained 15.01% over the past year. The stock has been range-bound between roughly $43.14 and $48.49 since late July 2026, suggesting a tentative consolidation base is forming after the steep decline, but the lack of upside momentum and the persistent negative relative strength argue against calling a durable reversal yet.
Key technical levels are well defined. Support sits at the 52-week low of $35.13, with a nearer consolidation floor around $43.14 (the August 2026 low); resistance is anchored at the 52-week high of $70.70, with intermediate resistance near $48.49 (the September 2026 swing high). A breakout above $48.49 on volume would be the first meaningful sign of trend repair, while a breakdown below $43 would likely open the door to retesting the $35 low. Volatility is a critical consideration: beta of 0.755 indicates the stock is roughly 25% less volatile than the market on a daily basis, but the max drawdown of -37.69% shows that this lower beta has not protected investors from severe capital impairment — position sizing should account for the fact that idiosyncratic, company-specific risk (leverage, impairments, cyclical chemical pricing) is dominating the risk profile here.
Beta
0.76
0.76x market volatility
Max Drawdown
-37.7%
Largest decline past year
52-Week Range
$35-$71
Price range past year
Annual Return
+15.8%
Cumulative gain past year
| Period | CE Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | +1.0% |
| 3m | -1.7% | +2.9% |
| 6m | -27.2% | +8.6% |
| 1y | +15.8% | +14.6% |
| ytd | +12.7% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CE Fundamental Analysis
The revenue trajectory is stagnating to slightly declining. Most recent quarterly revenue (Q1 2026, ended 2026-03-31) was $2.337 billion, down 2.18% year over year from $2.389 billion in Q1 2025. The multi-quarter trend shows revenue oscillating in a narrow band — $2.532 billion in Q2 2025, $2.419 billion in Q3 2025, $2.204 billion in Q4 2025, and $2.337 billion in Q1 2026 — with no clear growth inflection. Segment data shows Engineered Materials at $1.325 billion and the Acetyl Chain at $1.036 billion, meaning the specialty materials business is now the larger contributor; the investment case hinges on whether Engineered Materials can offset persistent weakness in the commodity-linked Acetyl Chain, and the flat-to-down top line suggests neither segment is currently providing growth leadership.
Profitability is thin and volatile, with reported results distorted by large non-cash charges. Q1 2026 net income was $44 million on $2.337 billion of revenue (net margin of just 1.88%), with gross margin of 18.96% and operating margin of 8.09%. Gross margin has compressed from 21.13% in Q2 2025 and 21.54% in Q3 2025 to 18.96% in Q1 2026, a roughly 260 basis point deterioration over three quarters. The trailing picture is far worse: trailing net margin is -12.21% and trailing EPS is -$0.25, reflecting the catastrophic Q3 2025 loss of $1.357 billion (EPS -$12.39) and Q4 2024 loss of $1.914 billion (EPS -$17.50), both driven by impairments and other charges rather than operating cash losses. The key question is whether the Q1 2026 return to positive net income ($44 million) and positive operating income ($189 million) marks a genuine earnings normalization, given that forward EPS estimates of roughly $11.95 imply a dramatic recovery from trailing levels.
Balance sheet leverage is the single largest fundamental risk. Debt-to-equity stands at 3.19x, total debt-to-capitalization is 75.5%, and the company-equity multiplier is 5.35x — an extremely levered capital structure for a cyclical chemical producer. Interest expense of $183 million in Q1 2026 consumed nearly all of the $189 million in operating income, leaving interest coverage of just 1.03x, which is dangerously thin. Liquidity is adequate but not comfortable: current ratio of 1.55 and cash of $1.758 billion at Q1 2026 end, up from $1.263 billion at year-end 2025 thanks to $493 million of asset-sale proceeds. Free cash flow is the bright spot — TTM FCF of $878 million and Q1 2026 FCF of $10 million (after $66 million of capex) — but ROE of -28.77% and ROA of 2.57% show that returns on capital remain deeply impaired, and the company's ability to deleverage depends on sustained FCF generation in a soft pricing environment.
Quarterly Revenue
$2.3B
2026-03
Revenue YoY Growth
-2.2%
YoY Comparison
Gross Margin
19.0%
Latest Quarter
Free Cash Flow
$878000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CE Overvalued?
Because trailing net income is negative (trailing EPS of -$0.25, trailing PE of -3.97x), the PE ratio is not meaningful as a primary metric, so the PS ratio is the appropriate lead valuation gauge. Celanese trades at a PS ratio of 0.485x and a price-to-book of 1.14x, with EV/Sales of 1.679x and EV/EBITDA of 55.82x — the latter inflated by depressed trailing EBITDA. The forward PE of 7.19x is the most informative multiple: it implies the market expects a dramatic earnings recovery from the current loss-making trailing base to forward EPS of roughly $11.95, a gap that reflects either substantial optimism about margin normalization or a market that is pricing the stock off trough-cycle earnings power rather than current results.
Relative to the specialty chemicals sector, the valuation appears cheap on most metrics. A PS ratio of 0.485x and P/B of 1.14x are well below the multiples typically commanded by specialty chemical peers, which often trade at 1.5-2.5x sales and 2-3x book, implying a discount of roughly 50-70% on sales and 40-60% on book. The forward PE of 7.19x also screens at a deep discount to the broader market and to quality chemical peers. However, this discount is at least partially justified: negative trailing margins, 3.19x debt-to-equity, 1.03x interest coverage, and a -28.77% ROE are materially inferior to the profitability and balance-sheet profiles of most specialty chemical comparables, so the market is applying a leverage-and-quality discount rather than mispricing the stock outright.
Historical context reinforces the de-rating story. Celanese's PS ratio has collapsed from 5.61x in Q3 2024 and 3.19x in Q4 2024 to 0.485x today, and its P/B has fallen from 2.04x in Q3 2024 to 1.14x now — both near multi-year lows. The historical PE band is unusable given the loss periods, but the P/B of 1.14x is close to the lowest level in the dataset (versus 4.36x in Q4 2021 and 2.64x in Q1 2024). This places the stock at the bottom of its own historical valuation range, which could signal a genuine value opportunity if earnings normalize as forward estimates suggest — or, alternatively, reflect the market's view that the balance sheet and cyclical earnings risk warrant a permanently lower multiple.
PE
-4.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 4x~62x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
48.7x
Enterprise Value Multiple
Investment Risk Disclosure
Celanese faces severe financial and operational risks stemming from its highly leveraged balance sheet. With debt-to-equity at 3.19x and interest coverage of just 1.03x, the company's $183 million quarterly interest expense nearly consumes all operating income. This leaves minimal cushion for any decline in earnings or cash flow. Additionally, revenue is concentrated in cyclical end markets: the Acetyl Chain segment ($1.04 billion quarterly revenue) is commodity-linked and subject to volatile pricing, while Engineered Materials ($1.33 billion) depends on automotive and industrial demand. The company's gross margin has compressed by 260 basis points over three quarters to 18.96%, and trailing net margin is deeply negative at -12.21%, reflecting impairment charges and operational challenges. Without sustained free cash flow generation, the company risks violating debt covenants or needing dilutive equity raises.
Market and competitive risks are significant given the company's premium valuation relative to its own history and the sector. The PS ratio of 0.485x is near multi-year lows, but this discount is justified by negative ROE (-28.77%) and high leverage compared to specialty chemical peers. The stock's beta of 0.755 suggests lower market correlation, but its max drawdown of -37.69% shows it is not immune to severe idiosyncratic shocks. Competitive pressures in acetic acid and derivatives could intensify if global capacity expands, particularly from low-cost producers in Asia. Regulatory risks include environmental compliance costs and potential tariffs affecting trade flows. Recent news highlights macro uncertainty around Fed policy, with markets pricing a 92% chance of no March rate change, which could keep borrowing costs elevated and pressure highly levered companies like Celanese.
The worst-case scenario involves a combination of weakening demand, margin compression, and a liquidity crunch. If acetyl chain pricing deteriorates further and Engineered Materials volumes decline due to a recession, EBITDA could fall below the level needed to cover interest and capex, leading to a free cash flow deficit. This could trigger credit rating downgrades, higher borrowing costs, and a potential equity dilution. In such a scenario, the stock could retest its 52-week low of $35.13, representing a 20.5% decline from the current price of $44.19. More extreme downside to the analyst low target of $45 is already near current levels, but if losses recur, the stock could fall below $35, implying a loss of 20% or more. The max drawdown of -37.69% over the past year illustrates the potential severity of a downturn.
FAQ
The key risks include: 1) Financial risk: Debt-to-equity of 3.19x and interest coverage of 1.03x mean that a decline in operating income could lead to covenant violations or liquidity issues. 2) Operational risk: Revenue is stagnant (Q1 2026 down 2.18% YoY) and gross margins have compressed to 18.96%, with no clear growth catalyst. 3) Market risk: The stock has underperformed SPY by 48.37 percentage points over six months, and its beta of 0.755 does not protect against idiosyncratic shocks, as shown by a max drawdown of -37.69%. 4) Company-specific risk: The company has a history of large impairment charges (Q3 2025 loss of $1.36 billion, Q4 2024 loss of $1.91 billion), which could recur if market conditions worsen. These risks are ranked from most severe (financial) to least severe (company-specific), but all are significant.
Our 12-month forecast for CE includes three scenarios: Bull case (25% probability) with a target range of $70-$86, assuming successful deleveraging and margin recovery; Base case (50% probability) with a target range of $55-$65, assuming gradual earnings recovery in line with analyst estimates; Bear case (25% probability) with a target range of $35-$45, assuming a recession and failure to deleverage. The base case is most likely, with a target of $63.12 (analyst average), implying 42.8% upside. The key assumption is that forward EPS of $11.95 is achieved, driven by cost savings and stable demand. However, the wide range reflects high uncertainty, and investors should monitor quarterly earnings for signs of progress.
CE appears undervalued on most metrics. The PS ratio of 0.485x is near multi-year lows, compared to 5.61x in Q3 2024, and the P/B ratio of 1.14x is well below its historical average of 2-4x. The forward PE of 7.19x is significantly below the broader market and specialty chemical peers, which often trade at 15-20x forward earnings. However, this discount is justified by the company's negative trailing net margin of -12.21%, high leverage (debt-to-equity of 3.19x), and negative ROE of -28.77%. The market is pricing in a high probability of financial distress or a prolonged earnings downturn. If the company achieves its forward EPS estimate of $11.95, the stock would be deeply undervalued; if it fails, the current price may be fair or even optimistic. Thus, the valuation is contingent on the success of the turnaround.
Whether CE is a good buy depends on your risk tolerance and investment horizon. The stock trades at a forward PE of 7.19x, implying significant undervaluation if earnings recover to the estimated $11.95 per share. Analyst consensus target of $63.12 offers 42.8% upside, but the low target of $45 is only 1.8% above the current price, highlighting downside risk. The company's debt-to-equity of 3.19x and interest coverage of 1.03x are major red flags that could lead to financial distress if earnings disappoint. For risk-tolerant investors seeking deep value with a 2-3 year horizon, CE could be a good buy on further weakness, but it is not suitable for conservative portfolios. The risk/reward is skewed toward high risk until there is clear evidence of sustainable profitability and deleveraging.
CE is more suitable for long-term investment (2-3 years) for investors with high risk tolerance, as the turnaround thesis requires time to play out. The company's beta of 0.755 suggests lower volatility than the market, but its max drawdown of -37.69% and recent underperformance indicate significant idiosyncratic risk. The dividend yield is negligible at 0.28%, so income is not a reason to hold. Earnings visibility is low due to cyclical end markets and high leverage, making short-term trading risky. A minimum holding period of 2-3 years is recommended to allow for potential deleveraging and earnings normalization. Short-term traders might exploit volatility around earnings, but the risk of further downside is substantial. Overall, CE is a speculative long-term value play, not a short-term momentum stock.